Yuri Fesko, MD

Yuri Fesko, M.D., is Senior Vice President and Chief Medical Officer (CMO) of Quest Diagnostics. He assumed the role of CMO in December 2023.

As CMO, Dr. Fesko is responsible for overseeing medical affairs, including clinical development and health plan policy support for new services and care delivery models. He also leads scientific communications for the company’s medical team of approximately 600 M.D.s and Ph.D.s.

Since joining Quest in 2016, Dr. Fesko has held several roles of increasing responsibility, most recently as Vice President of Medical Affairs and Senior Medical Director for the company’s oncology services.

Board certified in oncology, hematology and internal medicine, Dr. Fesko led clinical development of several innovations for Quest, including the company’s 500 gene somatic tumor next-generation sequencing panel as well as the company’s decentralized clinical trials model. He also pioneered the company’s precision pathways model of care, which helps oncologists and pathologists at health systems speed guideline-based biomarker testing for advanced cancers. In addition, he led clinical research on the minimal residual disease (MRD) test technology developed by Haystack Oncology, informing Quest’s decision to acquire the company in 2023 to establish a position in cancer recurrence testing.

Prior to joining Quest, Dr. Fesko was medical director of oncology for Duke Cancer Center in Raleigh, N.C., where he focused on genitourinary oncology and multiple myeloma, and was chief of oncology for Wake County, N.C. Dr. Fesko completed his fellowship in hematology and oncology and earned his medical and bachelor's degrees from Case Western Reserve University in Cleveland. He is author of multiple peer reviewed publications.